1 in 6 people in NYC (1.4 million) rely on daily emergency food. (Source: Robin Hood Foundation)

News

  • Study Reveals Strongest Links Yet Between Genes And ADHD Risk
    March 25, 2019

    By analyzing the DNA of more than 55,000 people, scientists from the Broad Institute of MIT and Harvard, Massachusetts General Hospital, and more than 60 additional institutions worldwide have identified 12 regions of the genome that raise the risk of ADHD, providing valuable biological insights. In their publication the researchers note that these variants reveal important insights into the biology behind ADHD risk, and that the many of these variants also influence an individual's risk or likelihood for a variety of psychiatric, metabolic, and behavioral traits. "These findings represent the culmination of over a decade of genome-wide association studies for ADHD, and the willingness of the community of ADHD geneticists to work together and share data to advance our understanding of why people develop ADHD," said Benjamin Neale, an institute member at the Broad Institute and core faculty member at MGH.

    Read more at broadinstitute.org
  • Mayo Clinic Implements New Regenerative Therapeutics Program
    March 25, 2019

    In a recent article, a team of Mayo Clinic scientists, including Dr. Shane Shapiro, propose a new model in regenerative medicine therapies to address three of the traditional obstacles to delivering regenerative care, (including deficits in patient education, the challenge of studying and treating a wide variety of both common and less-common diseases, and the lack of high-quality RWE in regenerative medicine in support of translation.) The Regenerative Therapeutics Program will present opportunities for all medical specialties to participate in the translation of regenerative and cell-based therapies into practice. Support for this project was provided by Gerstner Philanthropies and the Mayo Clinic Center for Regenerative Medicine.

    Hear more on this topic from Dr. Shapiro
  • Scientists Call For ‘Global Moratorium’ On Heritable Genome Editing
    March 14, 2019

    A group of 18 prominent scientists and bioethicists from seven countries, including Eric Lander of the Broad Institute, are calling for a temporary ban on all clinical uses of human germline editing (changing heritable DNA to make genetically modified children.) Their call, which has been endorsed by Francis Collins, director of the U.S. National Institutes of Health, calls for an "international framework in which nations, while retaining the right to make their own decisions, voluntarily commit to not approve any use of clinical germline editing unless certain conditions are met." The proposed 5-year ban would not apply to genome editing to treat diseases or germline editing for research that does not involve implanting embryos into a person's uterus.

    Read more at nature.com
  • Gerstner Family CDA Recipient’s Research Finds Ethnoracial Differences in Alzheimer’s Disease
    February 25, 2019

    The research of Dr. Melissa Murray, a Gerstner Family Career Development Award recipient, and her team of fellow Mayo Clinic researchers found Hispanic-American patients with Alzheimer’s tend to survive significantly longer with the disease than other ethnoracial groups, according to a study in Alzheimer's & Dementia: The Journal of the Alzheimer's Association. The findings also prompt the next stage of investigations, looking at factors that may influence survival in Hispanic-American patients.

    Read more at mayoclinic.org
  • Broad Institute launches Gerstner Center for Cancer Diagnostics
    February 20, 2019

    The Broad Institute of MIT and Harvard have announced a new $15 million commitment by Louis V. Gerstner, Jr. to create the Gerstner Center for Cancer Diagnostics at the Broad Institute. The Gerstner Center aims to advance blood-based biopsies for tracking disease progression and pursue other cancer diagnostics that have the potential to benefit millions of patients worldwide. The new Center builds upon a major effort at Broad focused on elucidating the mechanisms of cancer drug resistance, launched by a $10 million commitment from the Gerstner Family Foundation in 2015.

    Read more at broadinstitute.org